• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P53 缺失可能驱动多发性骨髓瘤的临床演变和治疗反应。

P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.

机构信息

Servicio de Hematología, Hospital Universitario, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.

出版信息

Eur J Haematol. 2010 Apr;84(4):359-61. doi: 10.1111/j.1600-0609.2009.01399.x. Epub 2009 Dec 14.

DOI:10.1111/j.1600-0609.2009.01399.x
PMID:20002730
Abstract

We report a patient with multiple myeloma presenting with a paraspinal plasmacytoma with a marked dissociation between the response obtained in bone marrow (BM) infiltration and that achieved in soft tissue masses. While a complete remission was reached and maintained in BM, extramedullary plasmacytomas were refractory to every line of treatment. Genetic analysis identified the presence of t(4;14) and RB deletion in myeloma cells of both origins. However, a P53 deletion was only detected in plasma cells from extramedullary plasmacytomas. This finding suggests that P53 deletion has a role in the lack of treatment response of extramedullary plasmacytomas.

摘要

我们报告了一例多发性骨髓瘤患者,其脊柱旁浆细胞瘤的骨髓浸润和软组织肿块的缓解程度明显分离。虽然骨髓完全缓解并维持,但髓外浆细胞瘤对每一线治疗均耐药。基因分析发现两种起源的骨髓瘤细胞均存在 t(4;14)和 RB 缺失。然而,仅在外髓浆细胞瘤的浆细胞中检测到 P53 缺失。这一发现表明 P53 缺失在外髓浆细胞瘤缺乏治疗反应中起作用。

相似文献

1
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.P53 缺失可能驱动多发性骨髓瘤的临床演变和治疗反应。
Eur J Haematol. 2010 Apr;84(4):359-61. doi: 10.1111/j.1600-0609.2009.01399.x. Epub 2009 Dec 14.
2
Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma.以脑内浆细胞瘤为首发表现的多发性骨髓瘤病例研究。
Neuro Oncol. 2007 Jul;9(3):370-2. doi: 10.1215/15228517-2007-008. Epub 2007 May 23.
3
Establishment and characterization of a cytogenetically complex Chinese multiple myeloma-derived cell line with homozygous p53 deletion and cyclin E overexpression.建立并鉴定一株具有细胞遗传学复杂性、p53纯合缺失和细胞周期蛋白E过表达的中国多发性骨髓瘤来源细胞系。
Int J Oncol. 2004 May;24(5):1141-8.
4
Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.一名患有t(4;14)易位多发性骨髓瘤患者的自发缓解
J Clin Oncol. 2009 Nov 20;27(33):e194-7. doi: 10.1200/JCO.2009.22.0392. Epub 2009 Oct 5.
5
[Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].[荧光原位杂交法对多发性骨髓瘤患者分子变化的研究]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Oct;27(5):567-70. doi: 10.3760/cma.j.issn.1003-9406.2010.05.020.
6
Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma.p53、p21/Waf-1、Rb、p16和Ki67蛋白在多发性骨髓瘤中的免疫组化表达
Anticancer Res. 2000 Nov-Dec;20(6B):4619-25.
7
Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics.原发性髓外浆细胞瘤:间期细胞遗传学揭示的与多发性骨髓瘤的异同
Haematologica. 2008 Apr;93(4):623-6. doi: 10.3324/haematol.12005. Epub 2008 Mar 6.
8
Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.采用流式细胞术检测t(4;14)多发性骨髓瘤患者骨髓及循环浆细胞中成纤维细胞生长因子受体3的表达并进行随访。
Br J Haematol. 2007 Feb;136(4):609-14. doi: 10.1111/j.1365-2141.2006.06479.x.
9
Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.遗传风险可识别出无法从自体干细胞移植中获益的多发性骨髓瘤患者。
Bone Marrow Transplant. 2005 Nov;36(9):793-6. doi: 10.1038/sj.bmt.1705131.
10
Gastric involvement of plasmacytoma associated with t(4:14) and chromosome 13 deletion.伴有t(4:14)和13号染色体缺失的浆细胞瘤的胃受累情况。
Leuk Lymphoma. 2006 Sep;47(9):1973-5. doi: 10.1080/10428190600709390.

引用本文的文献

1
Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment.骨髓之外:多发性骨髓瘤髓外疾病的治疗方法综述及微小残留病评估的意义
J Med Life. 2025 Jun;18(6):536-544. doi: 10.25122/jml-2025-0104.
2
Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.多发性骨髓瘤诊断时及疾病过程中的髓外病变
Int J Hematol. 2025 Mar 3. doi: 10.1007/s12185-025-03958-6.
3
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.
从血液系统恶性肿瘤中p53的调控到去调控:对诊断、预后和治疗的影响
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
4
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.新型抗B细胞成熟抗原α-鹅膏蕈碱抗体药物偶联物HDP-101在17p缺失骨髓瘤模型中显示出优于贝兰他单抗马福汀的活性和增强的疗效。
Res Sq. 2024 Jan 11:rs.3.rs-3843028. doi: 10.21203/rs.3.rs-3843028/v1.
5
Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution.初诊时和首次复发时多发性骨髓瘤中的骨旁和骨髓外浆细胞瘤:来自学术机构的 50 年经验。
Blood Cancer J. 2022 Sep 16;12(9):135. doi: 10.1038/s41408-022-00730-5.
6
Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma.循环肿瘤细胞、游离DNA和肿瘤衍生血小板作为多发性骨髓瘤液体活检中可靠的预后和管理生物标志物
Cancers (Basel). 2022 Aug 26;14(17):4136. doi: 10.3390/cancers14174136.
7
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.多发性骨髓瘤免疫基因组异质性的时空评估。
Blood Adv. 2023 Mar 14;7(5):718-733. doi: 10.1182/bloodadvances.2022007457.
8
Extramedullary disease in multiple myeloma: a systematic literature review.多发性骨髓瘤中的髓外疾病:系统文献回顾。
Blood Cancer J. 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3.
9
Identification of patients at high risk of secondary extramedullary multiple myeloma development.识别发生继发性髓外多发性骨髓瘤高风险的患者。
Br J Haematol. 2022 Feb;196(4):954-962. doi: 10.1111/bjh.17925. Epub 2021 Nov 2.
10
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease.基于卡非佐米的治疗策略在伴有髓外疾病的复发/难治性多发性骨髓瘤管理中的应用
Cancers (Basel). 2020 Apr 23;12(4):1035. doi: 10.3390/cancers12041035.